Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Financing Activities: 2024-2025

Historic Cash from Financing Activities for Kura Oncology (KURA) over the last 1 years, with Jun 2025 value amounting to $515,000.

  • Kura Oncology's Cash from Financing Activities fell 83.06% to $515,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $3.7 million, marking a year-over-year change of. This contributed to the annual value of $154.4 million for FY2024, which is 62.92% up from last year.
  • Kura Oncology's Cash from Financing Activities amounted to $515,000 in Q2 2025, which was up 260.14% from $143,000 recorded in Q1 2025.
  • In the past 5 years, Kura Oncology's Cash from Financing Activities registered a high of $148.4 million during Q1 2024, and its lowest value of $143,000 during Q1 2025.
  • For the 2-year period, Kura Oncology's Cash from Financing Activities averaged around $25.8 million, with its median value being $1.5 million (2024).
  • Data for Kura Oncology's Cash from Financing Activities shows a maximum YoY crashed of 99.90% (in 2025) over the last 5 years.
  • Over the past 2 years, Kura Oncology's Cash from Financing Activities (Quarterly) stood at $806,000 in 2024, then tumbled by 83.06% to $515,000 in 2025.
  • Its Cash from Financing Activities stands at $515,000 for Q2 2025, versus $143,000 for Q1 2025 and $806,000 for Q4 2024.